Table 3.
Clinical characteristics of patients with GC/GEJC/EAC, HER2 status negative/unknown, on first-line treatment
| Disease status | Total | France | Germany | UK | US | Japan | China |
|---|---|---|---|---|---|---|---|
| n = 682 | n = 168 | n = 146 | n = 145 | n = 99 | n = 36 | n = 88 | |
| Time since initial diagnosis, months | 625 | 156 | 135 | 129 | 86 | 31 | 88 |
| Mean (SD) | 6.3 (13.0) | 6.2 (10.0) | 5.3 (6.2) | 3.3 (3.4) | 6.4 (13.2) | 10.3 (12.4) | 11.3 (26.3) |
| Median (IQR) | 3 (2–6) | 3 (2–5) | 3 (2–5) | 2 (2–4) | 3 (2–5) | 6 (2–11) | 6 (3–14) |
| Time since advanced diagnosis, months | 629 | 155 | 139 | 129 | 87 | 31 | 88 |
| Mean (SD) | 4.8 (7.6) | 4.5 (7.1) | 4.8 (5.6) | 3.1 (3.1) | 6.0 (13.1) | 8.5 (9.6) | 5.0 (7.1) |
| Median (IQR) | 3 (2–5) | 3 (2–4) | 3 (2–5) | 2 (2–3) | 3 (2–5) | 6 (2–10) | 3 (2–5) |
| ECOG at advanced diagnosis, n (%) | 679 | 168 | 143 | 145 | 99 | 36 | 88 |
| 0 | 98 (14.4) | 21 (12.5) | 8 (5.6) | 31 (21.4) | 11 (11.1) | 15 (41.7) | 12 (13.6) |
| 1 | 421 (62.0) | 101 (60.1) | 100 (69.9) | 102 (70.3) | 58 (58.6) | 15 (41.7) | 45 (51.1) |
| 2 | 152 (22.4) | 45 (26.8) | 35 (24.5) | 12 (8.3) | 23 (23.2) | 6 (16.7) | 31 (35.2) |
| Current ECOGa, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| 0 | 73 (10.7) | 13 (7.7) | 6 (4.1) | 27 (18.6) | 12 (12.1) | 9 (25.0) | 6 (6.8) |
| 1 | 388 (56.9) | 92 (54.9) | 76 (52.1) | 105 (72.4) | 58 (58.6) | 19 (52.8) | 38 (43.2) |
| 2 | 221 (32.4) | 63 (37.5) | 64 (43.8) | 13 (9.0) | 29 (29.3) | 8 (22.2) | 44 (50.0) |
| ECOG changeb, n (%) | 672 | 167 | 138 | 145 | 99 | 36 | 87 |
| Unchanged | 510 (75.9) | 132 (79.0) | 96 (69.6) | 129 (89.0) | 80 (80.8) | 24 (66.7) | 49 (56.3) |
| Changed | 162 (24.1) | 35 (21.0) | 42 (30.4) | 16 (11.0) | 19 (19.2) | 12 (33.3) | 38 (43.7) |
| TNM staging at advanced diagnosis, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| Stage IIIA | 74 (10.9) | 6 (3.6) | 28 (19.2) | 3 (2.1) | 10 (10.1) | 1 (2.8) | 26 (29.6) |
| Stage IIIB | 79 (11.6) | 8 (4.8) | 28 (19.2) | 2 (1.4) | 9 (9.1) | 1 (2.8) | 31 (35.2) |
| Stage IIIC | 72 (10.6) | 19 (11.3) | 16 (11.0) | 12 (8.3) | 11 (11.1) | 0 (0.0) | 14 (15.9) |
| Stage IV | 457 (67.0) | 135 (80.4) | 74 (50.7) | 128 (88.3) | 69 (69.7) | 34 (94.4) | 17 (19.3) |
| Current TNM staging, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| Stage IIIA | 37 (5.4) | 1 (0.6) | 15 (10.3) | 1 (0.7) | 8 (8.1) | 0 (0.0) | 12 (13.6) |
| Stage IIIB | 68 (10.0) | 8 (4.8) | 21 (14.4) | 1 (0.7) | 8 (8.1) | 0 (0.0) | 30 (34.1) |
| Stage IIIC | 78 (11.4) | 19 (11.3) | 15 (10.3) | 11 (7.6) | 10 (10.1) | 1 (2.8) | 22 (25.0) |
| Stage IV | 499 (73.2) | 140 (83.3) | 95 (65.1) | 132 (91.0) | 73 (73.7) | 35 (97.2) | 24 (27.3) |
| De novo vs recurrent disease, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| De novo | 552 (80.9) | 151 (89.9) | 107 (73.3) | 138 (95.2) | 87 (87.9) | 32 (88.9) | 37 (42.1) |
| Recurrent | 130 (19.1) | 17 (10.1) | 39 (26.7) | 7 (4.8) | 12 (12.1) | 4 (11.1) | 51 (58.0) |
EAC Esophageal adenocarcinoma, ECOG Eastern cooperative oncology group, GC Gastric cancer, GEJC Gastroesophageal junction cancer, HER2 Human epidermal growth factor receptor 2, IQR Interquartile range, SD Standard deviation, TNM Tumor, Nodes, Metastases, UK United Kingdom, US United States
ano patients had an ECOG status of 3 or 4
brelating to change in ECOG status from advanced diagnosis to current